JAMES (JIM) J. KELLY, Ph.D., is an attorney in the firm's Chemical Patent Prosecution and Patent Interferences practice groups. With a doctorate in chemistry, Dr. Kelly represents a broad range of foreign and domestic clients in the pharmaceutical, biotech and medical device manufacturing industries in both patent prosecution and interference matters.
Taking a proactive approach, Dr. Kelly works closely with his clients to identify intellectual property that will help them achieve their business goals and position them for success in the future. Additionally, he counsels his clients on patent portfolio development and protection strategies.
Dr. Kelly handles claims under 35 USC § 135 and civil actions under 35 USC § 146. His blend of deep technical knowledge, business acumen, legal skill and long-term relationships with United States Patent and Trademark Office (USPTO) Patent Examiners contribute to his success in obtaining patents and resolving interference disputes. Dr. Kelly represents clients before the USPTO, at the Board of Patent Appeals and Interferences (BPAI) and in district courts.
While obtaining his Ph.D. in chemistry, Dr. Kelly studied DNA and RNA recognition by synthetic molecules under the direction of Professor Peter B. Dervan.
Professional Affiliations
American Bar Association
American Chemical Society
American Intellectual Property Law Association (AIPLA)
Intellectual Property Owners Association
Licensing Executives Society
Virginia Bar Association
Experience
Representative Matters
Representing Novartis in a Section 146 action involving coatings in asthma inhalers. GlaxoSmithKline v. Novartis (case pending).
Successfully represented Novartis against GlaxoSmithKline in a case involving coatings in asthma inhalers. Ashurst v. Brugger, Interference No. 105,482.
Resources
News
Patent and Trademark Office Grants Earth Friendly Chemical's Request for Inter Partes Reexamination of Sears Petroleum Patent
Thursday, June 1, 2006
Using Interferences to Your Advantage: Sky Radio Network Interviews Dr. James Kelly
Wednesday, October 1, 2003